Printer Friendly

MDs OVERWHELMINGLY CHOOSE MERCK FOR INVESTMENT, FINDS STUDY BY BETA RESEARCH CORPORATION

 SYOSSET, N.Y., March 3 /PRNewswire/ -- Beta Research Corporation announces the results of a study completed with 195 randomly chosen physicians in private practice across the country. The field period of the study was Feb. 23 -26, 1993.
 Respondents were asked to assume that they were given $10,000 with which to make a long-term investment in a pharmaceutical company. Without being read any choices, they were asked to indicate in which one pharmaceutical company they would invest. Over half (53 percent) of the respondents, which included general practitioners, family practitioners, internists, cardiologists, and psychiatrists, chose Merck Sharpe & Dohme as the pharmaceutical company in which they would be most likely to invest. No other company garnered more than 10 percent of the responses:
 Firm Percent
 Merck Sharpe & Dohme 53
 Bristol-Meyers Squibb 10
 Pfizer 8
 Glaxo 6
 Ortho 3
 Lilly 2
 Parke-Davis 2
 Upjohn 2
 Abbott 1
 Burroughs Wellcome 1
 Genentech 1
 Hoechst-Roussel 1
 Roche 1
 Sandoz 1
 Schering 1
 None 3
 Don't Know 2
 There were no significant differences across the specialties.
 Beta Research Corp., a market research company, headquartered in New York, is a nationally recognized provider of market research services to pharmaceutical companies, advertising agencies, and health care publications.
 -0- 3/3/93
 /CONTACT: Christie Kennedy, or Caryl Kahn, 516-935-3800, both of Beta Research Corp./


CO: Beta Research Corporation ST: New York IN: MTC SU:

TM-LD -- NY004 -- 2298 03/03/93 09:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 3, 1993
Words:236
Previous Article:RAYTHEON, FLUOR TEAM FOR $2.2 BILLION THAILAND REFINERY PROJECT
Next Article:RHONE-POULENC PSSA AND PIC EXCHANGE OFFERS EXPIRE
Topics:


Related Articles
Chrysalis and MDS Announce Strategic Initiative; MDS Invests $5 Million (U.S.) In Chrysalis
Intercardia Seeks Resolution With Astra Pharmaceuticals of Product Conflict With Bextra(R) Collaboration for USA
FDA Panel Recommends Approval of Cancidas(R), Merck's Investigational Antifungal Drug.
MDS Pharma Services Announces the Addition of a New Industry Expert to Its Pharmacology Consulting Group.
MDS Pharma Services Expands Capabilities at Early Clinical Research Facility in Hamburg.
MDS Pharma Services Expands Early Clinical Research Facility in New Jersey As Part of Global Expansion Plans.
MDS Pharma Services Advances Bioanalysis Capabilities.
MDS Inc. Appoints Paul S. Anderson To Board.
MDS Pharma Services' Global Central Lab to launch Apollo.
First Phase III Clinical Trial Results of Safinamide in Advanced Parkinson's Disease to Be Presented at the Movement Disorder Society 13th...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters